Progyny, Inc. (NASDAQ:PGNY) Receives $27.73 Average Target Price from Analysts

Progyny, Inc. (NASDAQ:PGNY - Get Free Report) has received an average recommendation of "Hold" from the twelve research firms that are currently covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $27.73.

Several research analysts have recently commented on the stock. Leerink Partnrs lowered shares of Progyny from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 7th. Canaccord Genuity Group lowered shares of Progyny from a "buy" rating to a "hold" rating and lowered their price objective for the company from $37.00 to $24.00 in a research note on Wednesday, August 7th. Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price objective on shares of Progyny in a research note on Tuesday, October 1st. Leerink Partners lowered their price objective on shares of Progyny from $25.00 to $21.00 and set a "market perform" rating for the company in a research note on Thursday, September 19th. Finally, JMP Securities downgraded shares of Progyny from an "outperform" rating to a "market perform" rating in a research note on Thursday, September 19th.

Progyny Trading Down 3.0 %

Progyny stock traded down $0.50 during midday trading on Monday, hitting $16.35. 1,714,355 shares of the stock were exchanged, compared to its average volume of 1,374,870. Progyny has a fifty-two week low of $13.93 and a fifty-two week high of $42.08. The stock has a market capitalization of $1.56 billion, a price-to-earnings ratio of 26.87, a PEG ratio of 1.48 and a beta of 1.43. The stock's 50-day simple moving average is $19.85 and its 200 day simple moving average is $25.76.

Progyny (NASDAQ:PGNY - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.17 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.17. Progyny had a net margin of 5.54% and a return on equity of 11.97%. The firm had revenue of $304.09 million during the quarter, compared to analysts' expectations of $305.32 million. During the same period last year, the business earned $0.15 earnings per share. Progyny's revenue was up 8.8% compared to the same quarter last year. Equities analysts anticipate that Progyny will post 0.64 EPS for the current fiscal year.

Institutional Trading of Progyny

Several institutional investors have recently modified their holdings of the stock. Caprock Group LLC lifted its position in shares of Progyny by 5.3% during the 1st quarter. Caprock Group LLC now owns 6,288 shares of the company's stock worth $240,000 after buying an additional 319 shares during the last quarter. RiverPark Advisors LLC increased its holdings in shares of Progyny by 9.6% in the 2nd quarter. RiverPark Advisors LLC now owns 5,408 shares of the company's stock valued at $155,000 after acquiring an additional 474 shares during the period. State of Michigan Retirement System increased its holdings in shares of Progyny by 2.5% in the 1st quarter. State of Michigan Retirement System now owns 20,479 shares of the company's stock valued at $781,000 after acquiring an additional 500 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in shares of Progyny by 9.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 6,260 shares of the company's stock valued at $239,000 after acquiring an additional 543 shares during the period. Finally, Arizona State Retirement System increased its holdings in shares of Progyny by 2.6% in the 2nd quarter. Arizona State Retirement System now owns 24,313 shares of the company's stock valued at $696,000 after acquiring an additional 609 shares during the period. Hedge funds and other institutional investors own 94.93% of the company's stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.